Search

You searched for "innovation"

811 results found

Dogs and humans share a bladder cancer biomarker: a new discovery that opens doors for early detection and treatment

9 September 2025
A new scientific study has identified a new molecular biomarker that could help doctors detect aggressive early-stage bladder cancer, such as high-grade non-muscle invasive bladder cancer (NMIBC), in both dogs and humans. This discovery advances our knowledge of how aggressive...
European Urology journal front cover.

Tissue-based biomarkers steering clinical decisions in patients with urothelial cancer

2 July 2025 | | URO - Urologic Oncology
Biomarkers play an essential role in the diagnosis and treatment of urothelial cancer (UC), with PD-L1, FGFR, and MMR proteins being the most clinically established. These biomarkers, derived from histological specimens, guide therapeutic decisions for bladder cancer (BCa) and upper...

Action Bladder Cancer UK to open applications for bladder cancer research grants

14 October 2025 | Charities, Research & Development
Action Bladder Cancer UK (ABC UK) will open applications in November 2024 for its 2026 research funding programmes, supporting projects that improve the care, treatment, or diagnosis of bladder cancer. Grants are offered under two schemes. The Improving Outcomes for...

Action Bladder Cancer UK offering grants for bladder cancer research

20 January 2026
Action Bladder Cancer UK (ABC UK) is inviting applications for its 2026 research funding programmes, supporting projects that improve the care, treatment or diagnosis of bladder cancer. Grants are offered under two schemes. The Improving Outcomes for Patients Programme (IOPP)...

Action Bladder Cancer UK offers nursing grants for projects supporting bladder cancer

22 January 2026
Action Bladder Cancer UK (ABC UK) is inviting specialist urology and cancer nurses to apply for funding to deliver nurse-led projects that improve bladder cancer care, patient experience and treatment pathways. The ABC UK Nursing Grants Programme offers grants of...

Management of stage 1 non-seminomatous germ cell tumours

1 November 2014 | | URO - Urologic Oncology
Testicular cancer (TC) is the most successfully treated solid tumour, achieving a cure rate of 90-95% [1-3]. Testicular cancer is relatively rare with an incidence of 2207 cases in the UK in 2014 [4] and yet is the most common...

Urologist in the House!

2 March 2022 | | URO - Technology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). This month, I am joined once again by Kassie Ball to discuss the...

Supporting chronic cystitis patients through the winter

1 October 2020 | Contracts & Distributors
The current pandemic is causing severe disruption to the care of patients with non-life-threatening conditions.

Urological etymology

4 May 2023 | | URO - Technology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). I’ve always found the derivation of names fascinating. Anatomy lessons were made so...

Artificial intelligence in bladder cancer diagnostics

2 May 2025 | | URO - Urologic Oncology
Bladder cancer (BCa), ranking as the 10th most common cancer worldwide, poses a significant health burden with high morbidity and mortality [1]. Timely tumour detection and accurate evaluation are crucial for effective management, as the prognosis is dependent on the...

The expanding indications for ureteroscopy – ad maiora!

1 March 2019 | | URO - Endourology & Stones, URO - Paediatrics, URO - Technology
The management of urolithiasis is becoming a Herculean task for healthcare providers worldwide. The incidence of stone disease is rising, with predicted lifetime risk of 12% in males and 6% in females [1]. This rise relates to both improving imaging...

Focal therapy for prostate cancer – ready for prime time?

1 November 2016 | | URO - Basic Science Research, URO - Urologic Oncology
The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...